Experimental study on induction of renal cell carcinoma apoptosis by antisense oligonucleotide targeting survivin

Abstract

The effect of antisense oligonucleotide (ASODN) targeting survivin on renal cell carcinoma (RCC) apoptosis, proliferation and sensitivity to chemotherapeutic drugs was investigated. Antisense oligonacleotide targeting survivin was designed and composed. The cDNA of survivin was transfected into RCC cell lines ACHN and 769-P, respectively. They were both cultured in normal condition. After transfection, ACHN and 769-P cell lines were cultured in a 6-well culture plate. The cultured cells were divided into 6 groups. Twenty-four h after transfection, survivin protein expression was detected by Western blot. Apoptotic index (AI) and proliferative index (PI) were examined by flow cytometry. Rate of inhibition (IR) by chemotherapeutic drugs was determined by the colorimetric MTT cell viability/proliferation assay. The results showed AI and IR of chemotherapeutic drugs in ASODN groups were significantly higher than those in the groups without ASODN. There were statistical differences between ASODN groups and control groups (P< 0.05), but there was no difference among control groups (P>0.05). The PI in the ASODN groups was significantly lower than that in the control groups with the difference being statistically significant (P<0.05). In addition, there were no differences among control groups. It was concluded that the expression of survivin could be down-regulated in 2 cell lines after ASODN transfection. Antisense oligonucleotide targeting survivin could induce RCC apoptosis, inhibit cell proliferation and sensitize RCC to chemotherapy.

Keywords

antisense oligonucleotide / survivin / apoptosis / renal cell carcinoma

References

[1] MesriM, WaliN R, LiJ, et al.. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest, 2001, 108: 991-991

[2] GrossmanD, KimP J, BlancO P, et al.. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of P53. J Clin Invest, 2001, 108: 981-981

[3] OlieR A, Simoes-WustA P, BaumannB, et al.. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 2000, 60: 2805-2805

[4] HanR. Research of Anti-tumor Drug and Experimental Technology, 1997, Beijing, Press of Peoples Health

[5] LebedevalI, SteinC A. Antisense oigonucleotides: promise and reality. Ann Rev Pharmacol Toxicol, 2001, 41: 403-403

[6] DeverauxQ L, SchendelS L, ReedJ C. Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin, 2001, 95: 57-57

[7] ShiY. Mechanisms of caspaes activation and inhibition during apoptosis. Mol Cell, 2002, 9: 459-459

[8] ReedJ C. The survivin saga goesin vivo. J Clin Invest, 2001, 108: 965-965

[9] FesikS W, ShiY. Structural biology. Controlling the caspases. Science, 2001, 294(5546): 1477-1477

[10] SuzukiA, HayashidaM, ItoT, et al.. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene, 2000, 19: 3225-3225

[11] AltieriD C, LiF. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest, 1999, 79: 1327-1327